Oligonucleotides: A novel area of interest for drug delivery in neurodegenerative diseases

Several neurodegenerative diseases, such as AD, PD, and HD are characterized by the malfunction and deposition of a particular protein. Treatments for these diseases have typically sought to alleviate the downstream effects of protein malfunction, but it appears most rational to target the source of that dysfunction, the afflicted protein itself, to obtain a very effective treatment outcome. Treatment of neurodegenerative diseases using a segment of RNA or oligonucleotides has become popular. Thanks to groundbreaking discoveries during the past decade, RNA has played an increasingly important role in human health and disease. Therefore, therapeutic regulation of RNA function must be developed as RNA becomes a more important target. Several RNA-targeting oligonucleotides can be used, including aptamers, ASOs, siRNAs, and miRNAs. The development of oligonucleotides in this area of research has been made possible by technological developments. A neurodegenerative illness could be halted or prevented if oligonucleotides attach to these linked target proteins and inhibit their buildup. This article focuses on oligonucleotide and its uses in neurodegenerative illnesses such as AD, PD, and HD.